New Horizon Research Group | Medical Affiliated Research Center

Research site

(Unclaimed)

Location

303 Williams Avenue South West Suite 511, Huntsville, Alabama, United States of America

Site insights

Top conditions

Top treatments

Testosterone

Estradiol

Vonoprazan

Lansoprazole

PRC-4016

ARD-0403

Desmopressin

DA-8159

Dapagliflozin

Cetrorelix Pamoate

Parent organization

This site is a part of New Horizon Research Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 72 total trials

A New Sildenafil Oral Film in Patients With Erectile Dysfunction

This is a Phase III, prospective, interventional, multi-center, randomized, double-blind, flexible-dose, placebo-controlled, parallel group clinical...

Active, not recruiting

Erectile Dysfunction

Drug: Sildenafil Oral Film 25 mg, 50 mg, 75 mg or 100 mg

Drug: Placebo

A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis (ASCEND)

This is a randomized, double-blind, placebo-controlled, parallel-dosing, multi-center study to evaluate the efficacy and safety of Rencofilstat as ev...

Active, not recruiting

Fibrosis, Liver

Nonalcoholic Steatohepatitis (NASH)

Drug: Rencofilstat

Drug: Placebo

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

The purpose of this study is to understand the safety and effects of a combined influenza and COVID-19 vaccine. This combined vaccine is compared to...

Active, not recruiting

COVID-19

Influenza

Biological: COVID-19 Vaccine

Biological: Investigational influenza vaccine

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates tar...

Active, not recruiting

COVID-19

SARS-CoV-2 Infection

Biological: BNT162b2 (Omi XBB.1.5)

Biological: BNT162b2 "(2024-2025 variant)"

Study to Evaluate the Efficacy, Immunogenicity, and Safety of RSVpreF in Adults. (RENOIR)

Efficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a...

Active, not recruiting

Lower Respiratory Tract Illness

Biological: RSVpreF

Biological: Placebo